Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3.

[1]  J. Tang,et al.  Comparing the Clinical Severity of Disease Caused by Enteroviruses and Human Parechoviruses in Neonates and Infants , 2019, The Pediatric infectious disease journal.

[2]  B. McMullan,et al.  High prevalence of developmental concern amongst infants at 12 months following hospitalised parechovirus infection , 2018, Journal of paediatrics and child health.

[3]  L. Jennings,et al.  Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants , 2017, Clinical Microbiology Reviews.

[4]  A. Saitoh,et al.  Human parechovirus type 3 infection: An emerging infection in neonates and young infants. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  P. Stockley,et al.  Genomic RNA folding mediates assembly of human parechovirus , 2017, Nature communications.

[6]  J. Rossen,et al.  Enterovirus and parechovirus infection in children: a brief overview , 2016, European Journal of Pediatrics.

[7]  C. Pannecouque,et al.  Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71. , 2016, European journal of medicinal chemistry.

[8]  Wienand A. Omta,et al.  Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C , 2016, Antimicrobial Agents and Chemotherapy.

[9]  A. Saitoh,et al.  Clinical utility of serum samples for human parechovirus type 3 infection in neonates and young infants: The 2014 epidemic in Japan. , 2016, The Journal of infection.

[10]  V. Sheppeard,et al.  Parechovirus Genotype 3 Outbreak among Infants, New South Wales, Australia, 2013–2014 , 2015, Emerging infectious diseases.

[11]  J. Neyts,et al.  Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP. , 2015, Antiviral research.

[12]  S. Midgley,et al.  Human Parechovirus Infection, Denmark , 2014, Emerging infectious diseases.

[13]  D. Pajkrt,et al.  Successful IVIG Treatment of Human Parechovirus-Associated Dilated Cardiomyopathy in an Infant , 2013, Pediatrics.

[14]  D. Pajkrt,et al.  Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development. , 2012, The Journal of general virology.

[15]  B. Westerhuis,et al.  Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. , 2010, Diagnostic microbiology and infectious disease.

[16]  R. Molenkamp,et al.  High Prevalence of Human Parechovirus (HPeV) Genotypes in the Amsterdam Region and Identification of Specific HPeV Variants by Direct Genotyping of Stool Samples , 2008, Journal of Clinical Microbiology.

[17]  R. Selvarangan,et al.  Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae). , 2018, Antiviral research.